Acumen Pharmaceuticals Inc (ABOS)

$3.4

Market is closed - opens 7 PM, 28 May 2024

Insights on Acumen Pharmaceuticals Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 67.0% return, outperforming this stock by 96.3%

Performance

  • $3.28
    $3.48
    $3.40
    downward going graph

    3.53%

    Downside

    Day's Volatility :5.75%

    Upside

    2.3%

    downward going graph
  • $1.81
    $11.31
    $3.40
    downward going graph

    46.76%

    Downside

    52 Weeks Volatility :84.0%

    Upside

    69.94%

    downward going graph

Returns

PeriodAcumen Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
-6.59%
-1.8%
0.0%
6 Months
45.3%
10.1%
0.0%
1 Year
-29.31%
13.2%
0.0%
3 Years
-82.01%
17.0%
-21.4%

Highlights

Market Capitalization
197.4M
Book Value
$4.61
Earnings Per Share (EPS)
-1.08
Wall Street Target Price
12.8
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-15.08%
Return On Equity TTM
-22.98%
Revenue TTM
329.0K
Revenue Per Share TTM
0.03
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
-32.4M
EBITDA
-61.1M
Diluted Eps TTM
-1.08
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.16
EPS Estimate Next Year
-1.44
EPS Estimate Current Quarter
-0.26
EPS Estimate Next Quarter
-0.27

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Acumen Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 276.47%

Current $3.40
Target $12.80

Technicals Summary

Sell

Neutral

Buy

Acumen Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals Inc
7.26%
45.3%
-29.31%
-82.01%
-82.01%
Moderna, Inc.
Moderna, Inc.
54.31%
114.37%
31.98%
-5.11%
673.49%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
11.53%
23.42%
35.86%
98.13%
219.88%
Novo Nordisk A/s
Novo Nordisk A/s
7.24%
30.97%
66.95%
238.66%
467.54%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
14.96%
30.49%
38.47%
120.96%
164.5%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals Inc
3.26
NA
NA
-1.16
-0.23
-0.15
NA
4.61
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.6
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.99
28.99
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.75
46.75
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.23
29.23
0.53
17.14
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals Inc
Buy
$197.4M
-82.01%
3.26
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$63.9B
673.49%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
219.88%
28.99
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$605.7B
467.54%
46.75
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$116.3B
164.5%
29.23
39.46%

Institutional Holdings

  • RA Capital Management, LLC

    24.85%
  • Sands Capital Ventures, LLC

    5.69%
  • Franklin Resources Inc

    5.59%
  • Millennium Management LLC

    4.38%
  • Rock Springs Capital Management LP

    3.83%
  • Vanguard Group Inc

    2.77%

Company Information

acumen is forging a new path towards safe and effective treatments for alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic amyloid-beta oligomers. our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (aβo) in synaptic dysfunction and neurodegeneration. these early insights have fostered decades of research on the biology of aβo at acumen and throughout the field. we are now on the on cusp of realizing the therapeutic potential of aβo targeted drugs.

Organization
Acumen Pharmaceuticals Inc
Employees
51
CEO
Mr. Daniel J. O'Connell M.B.A.
Industry
Healthcare

FAQs